This is a study of an investigational drug called YL201 as a possible treatment for advanced solid tumors. YL201 is thought to work by interrupting DNA replication in cancer cells, via focused delivery of the cytotoxic agent to the cancer cell. YL201 has shown some anti-cancer effects against cancer cells in the laboratory and in experimental animals. The main purpose of this study is to learn how safe the study drug and how well the study drug works.

The purpose of this research study is to look at a program that includes expert review of your tumor genetic test results. We want to see if this program can help your doctor identify better treatments or suitable clinical trials for your cancer. This is a hybrid decentralized study where some if not all assessments may be performed remotely or close to your home.

The purpose of this study is to look at the effectiveness of giving cemiplimab and XL092 before and after surgery for Anaplastic Thyroid Cancer.

The purpose of this research is to see if an experimental vaccine, which is created from your tumor tissue and dendritic cells isolated from your blood, can be an effective therapy when given after your standard treatment of surgery, chemotherapy, and radiation.

The purpose of this research is to measure the safety and effectiveness of ivonescimab compared to pembrolizumab. Ivonescimab is an antibody designed to block proteins that help cancer cells grow and spread, and by blocking these proteins may potentially slow cancer progression.

In this study, we are looking at a medicine called ZE50-0134 that might help treat people with relapsed and refractory CLL, SLL, or certain low-grade lymphomas. We want to see if taking different amounts of this medicine in capsule form is safe for patients.

Have you been diagnosed with metastatic cutaneous melanoma? Have you previously been treated for your melanoma, or maybe it can't be removed? If so, you might be eligible to take part in a study to compare how well a new drug, IMA203, can treat your cancer compared to your physician's choice of treatment.

To investigate the feasibility of the referral and engagement process in fatigue mitigation intervention for cancer-related fatigue among adults with CLL or other forms of indolent lymphoma.

We are looking for a dose of the APVO436 in combination with venetoclax and azacitidine that can be administered safely to participants who have been diagnosed with AML.

Are you and your partner dealing with prostate cancer? Healthy eating is an important part of managing prostate cancer. If you or your partner has been diagnosed with prostate cancer, you are invited to join this study. We will talk with both of you about how you discuss healthy eating, prepare meals, and eat together.